NKX2.2 Diagnostic Marker for Ewing's Sarcoma Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Ewing's sarcoma, such as molecular diagnostics testing for EWS/FLI and immunohistochemistry using CD99, are imperfect, missing approximately 15% of cases and lack specificity, while treatments like chemotherapy have low specificity and significant side effects, resulting in poor prognosis, especially for metastatic disease.
Innovation Solution
Identification and characterization of NKX2.2 as a diagnostic marker and therapeutic target, using specific oligonucleotide probes, primers, antibodies, and therapeutic agents to detect and interfere with NKX2.2 expression or activity in Ewing's sarcoma cells, enabling more precise diagnosis and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If molecular diagnostics test for EWS/FLI, then diagnostic coverage is achieved, but approximately 15% of Ewing's sarcoma cases are missed
Solution Approach 1:
The patent develops a panel of multiple diagnostic markers (NKX2.2, CD99, and other downstream genes) that can collectively detect all types of Ewing's sarcoma cases, including those missed by EWS/FLI testing alone. This multi-marker approach ensures universal detection across different translocation variants and cases without EWS/FLI fusion.
2Measurement precision
If CD99 immunohistochemistry is used, then diagnostic sensitivity is improved, but specificity decreases as similar tumors also express CD99
Solution Approach 1:
The patent identifies NKX2.2 as a marker with highly localized and specific expression in Ewing's sarcoma cells, distinguishing it from other tumors that may express CD99. This specific marker provides precise identification of Ewing's sarcoma without false positives from similar tumors.
3Reliability
If chemotherapy is used to treat Ewing's sarcoma, then micrometastatic deposits are targeted, but treatment specificity is low and significant side effects occur
Solution Approach 1:
The patent uses NKX2.2 as a specific intermediary target that mediates selective destruction of Ewing's sarcoma cells. By targeting this specific molecular marker rather than using non-specific chemotherapy, the treatment achieves high efficacy against cancer cells while minimizing harm to healthy tissues.
4Ease of operation
If current diagnostic and treatment methods are used, then standard care is provided, but prognosis remains poor with cure rates of 50-70% at best
Solution Approach 1:
The patent enables early and accurate identification of Ewing's sarcoma through NKX2.2 marker detection, allowing preliminary diagnosis before metastasis occurs. This early detection facilitates timely intervention with targeted therapies, significantly improving prognosis compared to standard care that often detects disease at later stages.
Data Source
AI summary
The present invention relates to methods and compositions for the detection and treatment of Ewing's sarcoma. In particular, the methods of detection relate to measuring in Ewing's sarcoma cells the expression of the NKX2.2 gene, as well as targets genes downstream of NKX2.2. The compositions and method of treatment for Ewing's sarcoma involve therapeutic agents that target the expression of the NKX2.2 gene or block the activity of the NKX2.2 protein. Also provided are methods of screening therapeutic agents that affect the expression of the NKX2.2 gene.